Peripheral blood mononuclear cells — the lymphocytes and monocytes isolated from whole blood — are foundational to modern biomedical research. They serve as the starting material for CAR-T and NK cell therapies, the substrate for vaccine immune-response testing, and the analytical tool of choice in oncology biomarker discovery, autoimmune disease research, and infectious disease studies. As cell and gene therapies move from early-stage experiments into late-phase clinical trials and commercial manufacturing, demand for reliable, high-quality PBMC products is accelerating across research, clinical, and industrial settings.
The global PBMC market was valued at $322.2 million in 2025 and is forecast to reach $577.2 million by 2031, expanding at a CAGR of 10.3% over the 2026–2031 period. That pace reflects the convergence of several durable trends: rising public and private R&D investment in oncology and immunology, expanding national biobanking programs, a sharp increase in cell and gene therapy clinical trials, and the growing adoption of precision medicine approaches that require longitudinal immune profiling from patient samples.
The companies shaping this market range from large diversified life science suppliers to focused specialists in biospecimen sourcing, cell separation technology, and CDMO services. The 10 companies profiled below represent the breadth of that landscape — from century-old scientific institutions to venture-backed innovators commercializing next-generation isolation platforms.
Market Context: Segments and Regional Leadership
Among product types, cryopreserved or frozen PBMCs hold the largest share at 40.4% of the 2025 market, generating $130.3 million and growing at a 10.3% CAGR. Consistent availability, reduced donor-to-donor immune variability, and improved post-thaw viability underpin this dominance. However, peripheral blood mononuclear cell isolation and viability kits are growing fastest, at an 11.3% CAGR from a $102.1 million base, as ready-to-use kits gain traction for their reproducibility and time savings. On the technology side, density gradient centrifugation remains the method of record at $221.9 million, while leukapheresis — capable of yielding 3 billion to 10 billion PBMCs per session — is expanding fastest at a 12.2% CAGR, reflecting the scale requirements of commercial cell therapy manufacturing.
By application, oncology leads at $114.0 million and a 11.9% CAGR, driven by rising global cancer burden and expanding investment in immunotherapy and personalized medicine. Immunology follows at $80.7 million, supported by autoimmune disease research and advances in flow cytometry, single-cell analysis, and multiomics. Geographically, North America commands a 42.3% share of the 2025 market, anchored by a mature clinical research ecosystem and a dense network of biopharmaceutical and contract research organizations. Europe grows at 10.4% through 2031, while Asia-Pacific registers the highest regional CAGR at 11.8%, propelled by expanding clinical trial activity — most notably the milestone in 2025 when Asia-Pacific surpassed North America in ongoing cell and gene therapy trials for the first time.
1. Charles River Laboratories
• Headquarters: Wilmington, Massachusetts, U.S.
• Founded: 1947
• Revenue: $4,015 million (FY2025)
• Employees: 18,500
• Focus: Research models and services, discovery and safety assessment, manufacturing solutions
Charles River Laboratories supports the PBMC market across research and therapeutic development through a broad product portfolio that includes Normal Cryopreserved PBMCs, GMP PBMCs, Irradiated PBMCs, Disease State Cryopreserved PBMCs, Mobilized Cryopreserved PBMCs, and Pooled Cryopreserved PBMCs. The company distributes these products across the U.S., Europe, Canada, and Asia-Pacific. A significant recent development is its membership in the Akadeum CDMO Alliance Program alongside ElevateBio, positioning Charles River to support scalable GMP cell therapy manufacturing using BACS microbubble-based cell separation technology.
2. Lonza
• Headquarters: Basel, Switzerland
• Founded: 1897
• Revenue: $7,879.9 million (FY2025)
• Employees: 16,866
• Focus: Cell and gene therapy CDMO, viral vector manufacturing, plasmid DNA production
Lonza competes in the PBMC market primarily through its position as a leading CDMO in the cell and gene therapy space. The company's manufacturing capabilities span lentivirus, AAV, adenoviral vectors, and plasmid DNA, with platforms designed to maximize vector production while ensuring potency, purity, and scalability. As demand for cell therapies requiring PBMC-derived starting materials grows — particularly CAR-T and TCR-engineered therapies — Lonza's broad CDMO service portfolio places it among the most strategically relevant contract manufacturers in this ecosystem.
3. Merck KGaA
• Headquarters: Darmstadt, Germany
• Founded: 1668
• Revenue: $23,866.8 million (FY2025)
• Employees: 62,461
• Focus: Life science tools and CDMO services, healthcare (oncology, neurology, fertility), electronics
Merck KGaA's Life Science segment — encompassing Science and Lab Solutions, Process Solutions, and Life Science Services — is the primary avenue for its participation in the PBMC market. The company has been actively expanding its gene transfer and cell therapy portfolio, including the acquisition of Mirus Bio for approximately $600 million in 2024 to strengthen transfection reagent capabilities. Merck KGaA is also pursuing partnerships and acquisitions to build out CRISPR-based therapy and mRNA vaccine offerings, supporting downstream demand for PBMC-based immune profiling and functional assays.
4. Cytiva
• Headquarters: Marlborough, Massachusetts, U.S.
• Founded: 1968
• Employees: 15,000
• Focus: Life sciences tools and bioprocessing, chromatography, filtration, cell culture, PBMC isolation products
Cytiva, a Danaher subsidiary, brings significant scale and infrastructure to the PBMC market through its integrated portfolio of bioprocessing and separation technologies. Operating across 41 countries with 36 manufacturing sites and 23 R&D centers, the company serves biopharmaceutical developers, contract manufacturers, and research institutions. Its PBMC isolation products sit within a broader biopharmaceutical development toolset that supports the full drug development value chain, from discovery through commercial manufacturing, giving Cytiva a distinctive position for customers seeking consolidated supplier relationships.
5. Miltenyi Biotec
• Headquarters: Bergisch Gladbach, Germany
• Founded: 1989
• Employees: 4,700
• Focus: Cell and gene therapy research and manufacturing, MACS technology, flow cytometry, automated cell processing, PBMC isolation
Miltenyi Biotec is a specialist in cell biology and cell therapy tools, with immunomagnetic separation (MACS technology) and automated PBMC isolation via the autoMACS NEO Separator among its core offerings. The company operates across 27 global locations with staff from more than 75 countries and a catalog of over 21,000 products. In 2024, Miltenyi established a Cell and Gene Therapy Centre of Excellence in Hyderabad, India, reflecting a deliberate move into the Asia-Pacific market as that region accelerates clinical trial activity and cell therapy commercialization.
6. Akadeum Life Sciences
• Headquarters: Ann Arbor, Michigan, U.S.
• Founded: 2014
• Focus: Buoyancy activated cell sorting (BACS) microbubble technology, PBMC isolation kits, cell therapy CDMO services, cell separation platforms
Akadeum Life Sciences is the developer of BACS microbubble technology, a proprietary approach to cell separation that isolates untouched PBMCs from leukopak material without density gradient centrifugation, reducing cell damage and enabling GMP-compliant workflows. In 2025 the company launched its CDMO Alliance Program with Charles River Laboratories and ElevateBio, and partnered with Cayman Chemical to broaden access to its isolation technologies. In 2026, Akadeum raised over $20 million led by Michigan Capital Network to fund further expansion of its cell separation platform and cell therapy commercialization efforts.
7. ATCC
• Headquarters: Washington, D.C., U.S.
• Founded: 1925
• Focus: Biological standards and reference materials, primary human cells including PBMCs, cell authentication, cGMP mammalian cell biorepository services
ATCC is a globally recognized biological standards organization with a long-standing role supplying authenticated cell products — including PBMCs — to pharmaceutical, biotechnology, and academic researchers. The organization recently received an NIH C06 Research Facilities Construction Grant and a Virginia Economic Development Partnership Commonwealth's Development Opportunity Fund grant to build a new biomanufacturing suite in Manassas, Virginia. The facility is intended for high-throughput production, storage, and distribution of biological standards and reagents, directly expanding ATCC's capacity to serve growing demand in vaccine, therapeutic, and diagnostic research.
8. BioIVT
• Headquarters: Woodbury, New York, U.S.
• Founded: 1995
• Focus: Biospecimen sourcing and supply, PBMC products, primary cells, tissues, exosomes, immunology and cell therapy research support
BioIVT is positioned as a Tier 1 supplier in the global PBMC market, offering fresh and cryopreserved PBMC products alongside non-human PBMCs and proprietary isolation kits. Its customer base spans pharmaceutical, biotechnology, and academic organizations across oncology, immunology, vaccine development, and cell and gene therapy research. In 2024, BioIVT acquired ZenBio, adding primary cells, exosomes, and additional blood-derived biospecimens to its portfolio and strengthening its depth across immunology and translational research applications.
9. BioLegend Inc.
• Headquarters: San Diego, California, U.S.
• Founded: 2002
• Focus: Antibodies, flow cytometry reagents, recombinant proteins, ELISA kits, magnetic separation systems, PBMCs
BioLegend operates as a subsidiary focused on supplying biotechnology research tools — antibodies, reagents, recombinant proteins, cytokines, ELISA kits, and magnetic separation systems — along with PBMCs for immunology, oncology, neuroscience, and stem cell biology applications. The company supports techniques including flow cytometry, western blotting, immunoprecipitation, ChIP, and microscopy, serving researchers in the U.S., Europe, Asia-Pacific, and beyond. Its broad reagent portfolio makes it a natural complement to PBMC-based workflows where downstream analysis tools and cell products are sourced from a single supplier.
10. CGT Global
• Headquarters: Folsom, California, U.S.
• Founded: 2010
• Focus: Biospecimen sourcing, frozen and fresh PBMCs, CD34+ cell products, liquid biopsy and cell-free DNA research support, drug development
CGT Global, which rebranded from StemExpress in 2024 to reflect its expanded focus on cell and gene therapy, operates an integrated network of donor collection centers, hospital partnerships, and cell manufacturing laboratories. The company supplies frozen and fresh PBMCs, CD34+ cells, and liquid biopsy materials to support drug development, transplant studies, immuno-oncology research, and advanced single-cell sequencing applications. Positioned as a Tier 1 competitor in the global PBMC market, CGT Global's vertically integrated collection and processing infrastructure supports the reliable supply chains that large-scale cell therapy programs require.
Conclusion
The global PBMC market is at an inflection point where established life science suppliers, specialized biospecimen companies, and technology innovators are all competing for position. Cryopreserved products and isolation kits anchor current revenues, but the fastest-growing opportunities are tied to cell and gene therapy manufacturing — where scale, GMP compliance, and consistent cell quality are non-negotiable. The companies profiled here are responding with facility expansions, strategic acquisitions, alliance programs, and novel separation technologies designed to meet those demands.
Looking ahead, the 10.3% CAGR projected through 2031 will be shaped by regional dynamics as much as product innovation. Asia-Pacific's emergence as the largest region for active cell and gene therapy trials signals a geographic shift that every major PBMC supplier will need to address. Meanwhile, advances in automated isolation, AI-enabled biobanking, and next-generation cryopreservation are progressively resolving the manual workflow bottlenecks and cold-chain complexity that have historically limited market expansion. The companies best positioned for the next phase will be those that combine supply reliability with the technical capabilities demanded by an increasingly sophisticated customer base.
Learn More and Take Action:
Consider becoming a member of the BCC Research library and gain access to our full catalog of market research reports in your industry. Not seeing what you are looking for? We offer custom solutions too, including our new product line: Custom Intelligence Services.
Contact us today to find out more.
